Melinta Therapeutics, Inc – Product Pipeline Review

Global Markets Direct’s, ‘Melinta Therapeutics, Inc – Product Pipeline Review – 2016’, provides an overview of the Melinta Therapeutics, Inc’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Melinta Therapeutics, Inc, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of Melinta Therapeutics, Inc

The report provides overview of Melinta Therapeutics, Inc including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses Melinta Therapeutics, Inc’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features Melinta Therapeutics, Inc’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate Melinta Therapeutics, Inc’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Melinta Therapeutics, Inc

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Melinta Therapeutics, Inc’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Melinta Therapeutics, Inc Snapshot 5

Melinta Therapeutics, Inc Overview 5

Key Information 5

Key Facts 5

Melinta Therapeutics, Inc - Research and Development Overview 6

Key Therapeutic Areas 6

Melinta Therapeutics, Inc - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Melinta Therapeutics, Inc - Pipeline Products Glance 11

Melinta Therapeutics, Inc - Late Stage Pipeline Products 11

Phase III Products/Combination Treatment Modalities 11

Melinta Therapeutics, Inc - Clinical Stage Pipeline Products 12

Phase II Products/Combination Treatment Modalities 12

Melinta Therapeutics, Inc - Early Stage Pipeline Products 13

Preclinical Products/Combination Treatment Modalities 13

Discovery Products/Combination Treatment Modalities 14

Melinta Therapeutics, Inc - Drug Profiles 15

delafloxacin 15

Product Description 15

Mechanism of Action 15

R&D Progress 15

radezolid 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

RX-02 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

RX-04 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

RX-05 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

RXP-792 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

RXP-873 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

RXP-763 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

RXP-766 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

RXP-770 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

RXP-793 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

RXP-808 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

Melinta Therapeutics, Inc - Pipeline Analysis 34

Melinta Therapeutics, Inc - Pipeline Products by Target 34

Melinta Therapeutics, Inc - Pipeline Products by Route of Administration 35

Melinta Therapeutics, Inc - Pipeline Products by Molecule Type 36

Melinta Therapeutics, Inc - Pipeline Products by Mechanism of Action 37

Melinta Therapeutics, Inc - Recent Pipeline Updates 38

Melinta Therapeutics, Inc - Dormant Projects 46

Melinta Therapeutics, Inc - Company Statement 47

Melinta Therapeutics, Inc - Locations And Subsidiaries 48

Head Office 48

Other Locations & Subsidiaries 48

Appendix 49

Methodology 49

Coverage 49

Secondary Research 49

Primary Research 49

Expert Panel Validation 49

Contact Us 49

Disclaimer 50

List of Tables

List of Tables

Melinta Therapeutics, Inc, Key Information 5

Melinta Therapeutics, Inc, Key Facts 5

Melinta Therapeutics, Inc – Pipeline by Indication, 2016 7

Melinta Therapeutics, Inc – Pipeline by Stage of Development, 2016 9

Melinta Therapeutics, Inc – Monotherapy Products in Pipeline, 2016 10

Melinta Therapeutics, Inc – Phase III, 2016 11

Melinta Therapeutics, Inc – Phase II, 2016 12

Melinta Therapeutics, Inc – Preclinical, 2016 13

Melinta Therapeutics, Inc – Discovery, 2016 14

Melinta Therapeutics, Inc – Pipeline by Target, 2016 34

Melinta Therapeutics, Inc – Pipeline by Route of Administration, 2016 35

Melinta Therapeutics, Inc – Pipeline by Molecule Type, 2016 36

Melinta Therapeutics, Inc – Pipeline Products by Mechanism of Action, 2016 37

Melinta Therapeutics, Inc – Recent Pipeline Updates, 2016 38

Melinta Therapeutics, Inc – Dormant Developmental Projects,2016 46

Melinta Therapeutics, Inc, Other Locations 48

List of Figures

List of Figures

Melinta Therapeutics, Inc – Pipeline by Top 10 Indication, 2016 7

Melinta Therapeutics, Inc – Pipeline by Stage of Development, 2016 9

Melinta Therapeutics, Inc – Monotherapy Products in Pipeline, 2016 10

Melinta Therapeutics, Inc – Pipeline by Target, 2016 34

Melinta Therapeutics, Inc – Pipeline by Route of Administration, 2016 35

Melinta Therapeutics, Inc – Pipeline by Molecule Type, 2016 36

Melinta Therapeutics, Inc – Pipeline Products by Mechanism of Action, 2016 37

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports